The effects of synthetic glucagon fragments on glucose-6-phosphate dehydrogenase. II.
- 1 January 1979
- journal article
- research article
- Published by Pharmaceutical Society of Japan in CHEMICAL & PHARMACEUTICAL BULLETIN
- Vol. 27 (11) , 2827-2831
- https://doi.org/10.1248/cpb.27.2827
Abstract
The glucagon fragment H-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr-OH (positions 22-29) was synthesized by a conventional method. Two glucagon fragments, H-His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-OH (positions 1-14) and the octapeptide fragment synthesized in this study were tested for inhibitory activity towards glucose-6-phosphate dehydrogenase. The octapeptide (positions 22-29) inhibited glucose-6-phosphate dehydrogenase activity by 18% at a concentration of 0.5 mg/ml. [Uremia in man is characterized by several metabolic disturbances including glucose metabolism abnormalities and hyperglucagonemia. The hyperglucagonemia may be due to decreased catabolism and renal excretion. Peptide fragments from glucagon degradation products may inhibit glycolytic enzymes.].This publication has 1 reference indexed in Scilit:
- Influence of uremia and hemodialysis on the turnover and metabolic effects of glucagon.Journal of Clinical Investigation, 1976